1. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. (15th July 2018) Authors: Blauvelt, A.; Lacour, J.‐P.; Fowler, J.F.; Weinberg, J.M.; Gospodinov, D.; Schuck, E.; Jauch‐Lembach, J.; Balfour, A.; Leonardi, C.L. Journal: British journal of dermatology Issue: Volume 179:Number 3(2018) Page Start: 623 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. (1st September 2018) Authors: Blauvelt, A.; Lacour, J.‐P.; Fowler, J.F.; Weinberg, J.M.; Gospodinov, D.; Schuck, E.; Jauch‐Lembach, J.; Balfour, A.; Leonardi, C.L. Journal: British journal of dermatology Issue: Volume 179:Number 3(2018) Page Start: 623 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗